Navigation Links
Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency
Date:6/30/2009

PORTON DOWN, England, June 30 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today successful independent testing for bovine viral diarrhoea (BVD) by the Veterinary Laboratories Agency to evaluate the performance of the Enigma FL (Field Laboratory).

BVD is considered to be one of the main threats to cattle (1), affecting the majority of herds in the UK. It is closely related to classical swine fever virus, a serious disease of pigs, and to border disease virus, which infects sheep.

The Enigma FL instrument was used to analyse more than 100 blood samples that had already been screened by antigen ELISA and a laboratory-based RT-PCR for the presence of the BVD virus. Approximately half of the samples were proved BVDV positive by the laboratory-based PCR. With the level of concordance between the two tests being above 97%, this confirmed the Enigma FL system can produce laboratory-standard results with a high degree of confidence.

The Enigma FL has been designed for easy operation. Tests are provided in a single-use cartridge that can be stored at room temperature. The Enigma FL provides a PCR result in less than one hour, a timescale needed to allow field-based & pen-side diagnosis. On-site testing removes delays from transport of samples to the laboratory, which can often take days. The system requires minimal training and its utility for "pen-side" testing for BVD has already been demonstrated.(2)

John McKinley, Chairman and CEO of Enigma, stated: "The Enigma Diagnostics tests could be deployed for the related viral diseases, such as classical swine fever, with minor modifications. The system itself is broadly applicable to many other veterinary pathogens, such as TB in cattle, bacterial infections and other viral infections, such as foot and mouth disease and avian influenza. Allowing vets to use advanced molecular diagnosis in the field will enhance their efficiency in managing endemic and exotic disease outbreaks identifying diseased animals and as importantly, non-infected ones and improve their surveillance capability."

(1) http://www.rvc.ac.uk/BVD/documents/BVD_Disease.ppt

(2) http://enigmadiagnostics.com/template2.php?page=news.php&m=4

    Contacts

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    US Contact:
    Richard Lewis Communications, Inc.
    212-827-0020
    Gregory Tiberend - Media
    gtiberend@rlcinc.com
    Cecelia Heer - Investors
    cheer@rlcinc.com

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive licence from the Defence Science and Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com.


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
2. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
3. Enigma Signs Real-Time PCR Licences With Applera
4. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
5. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
6. Enigma Diagnostics Announces the Opening of a United States Office
7. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
8. Strategic Diagnostics Updates Roth Conference Presentation Time
9. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
10. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
11. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Global Stem Cells Group ... stem cell treatment center in Quito, Ecuador, Feb. 24-March 6, 2016. The new facility ... the world. , Global Stem Cells Group CEO Benito Novas will host the ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Georgia World Congress Center in Atlanta, Georgia, will include 848 exhibitors (count as ... companies will be displaying products and services used by the scientific community in ...
(Date:2/12/2016)... SOUTH PLAINFIELD, N.J. , Feb. 12, 2016 ... today announced the second annual STRIVE (Strategies to ... for Duchenne muscular dystrophy (DMD). STRIVE provides funds ... collaborative programs that will make meaningful contributions to ... education or fostering development of future patient advocates. ...
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic ... Research and Discovery --> --> ... plan to sequence 100,000 individuals. It is intended to initially ... 7 of North and East Asian countries. ... project will focus on creating phased reference genomes for all ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
Breaking Biology News(10 mins):